Last reviewed · How we verify
GX-188E
At a glance
| Generic name | GX-188E |
|---|---|
| Also known as | DNA therapeutic vaccine, GX-188E administerd by eletrophoration, tirvalimogene teraplasmid, GX-188E administered by electrophoration |
| Sponsor | Genexine, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy (PHASE2)
- Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (PHASE2)
- The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer (PHASE1, PHASE2)
- Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
- Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) (PHASE2)
- Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia (PHASE2)
- Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
- Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |